GLP-1 has been shown in large trials to reduce cardiovascular events. Here's what 'reduced' actually means.

The headline data

Across multiple trials (LEADER, SUSTAIN-6, REWIND, SELECT), GLP-1 medications reduced major cardiovascular events by 12–14% in patients at high CV risk.

Why this matters in India

Indian patients develop coronary artery disease 5–10 years earlier than Western populations. A medication that reduces CV events while also addressing diabetes and obesity is unusually high-value here.

Who benefits most

Patients with diabetes + obesity + established CV disease or multiple risk factors. The reduction is on top of what statins + BP control + lifestyle already achieve.